Clinical Trial Detail

NCT ID NCT02849496
Title Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Her2-receptor negative breast cancer

Therapies

Olaparib

Atezolizumab + Olaparib

Age Groups: adult senior

No variant requirements are available.